Frazer, Pa., May 31 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq:
CEPH) today announced that the company will be added to the NASDAQ- 100
Index(R), effective as of the market open on Friday, June 1, 2007. Shares
of Cephalon will also be included in the PowerShares QQQ(TM)(Nasdaq: QQQQ).
"We are delighted to be recognized as part of the NASDAQ-100 Index,"
said J. Kevin Buchi, Executive Vice President and Chief Financial Officer.
"Listing in the NASDAQ-100 reflects significant achievements across our
business in recent years. We look forward to continuing growth as the
Company advances its mission of developing innovative medicine for
improving human health."
Launched in January 1985, the NASDAQ-100 Index includes 100 of the
largest non-financial domestic and international securities listed on The
NASDAQ Stock Market based on market capitalization. The PowerShares QQQ was
launched in March 1999 and represents ownership in the PowerShares QQQ
Trust. The Trust holds a portfolio of equity securities that compose the
Nasdaq-100 Index and aims to provide investment results that generally
correspond with the Nasdaq- 100 Index performance.
Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical
company dedicated to the discovery, development and marketing of innovative
products in four core therapeutic areas: central nervous system, pain,
oncology and addiction. A first time member of the Fortune 1000, Cephalon
currently employs approximately 3,000 people in the United States and
Europe. U.S. sites include the company's headquarters in Frazer,
Pennsylvania, and offices, laboratories or manufacturing facilities in West
Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis,
Minnesota. Cephalon's European headquarters are located in Maisons-Alfort,
France.
The company's proprietary products in the United States include:
PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet)
[C-II], TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone
for extended-release injectable suspension), GABITRIL(R) (tiagabine
hydrochloride), and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II].
The Company also markets numerous products internationally. Full
prescribing information on its U.S. products is available at
http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition,
this press release may contain forward-looking statements. Forward-looking
statements provide Cephalon's current expectations or forecasts of future
events. These may include statements regarding anticipated scientific
progress on its research programs; development of potential pharmaceutical
products; interpretation of clinical results; prospects for regulatory
approval; manufacturing development and capabilities; market prospects for
its products; sales, adjusted net income and basic adjusted income per
common share guidance; and other statements regarding matters that are not
historical facts, including the Company's expectations for continued growth
in the future. You may identify some of these forward-looking statements by
the use of words in the statements such as "anticipate," "estimate,"
"expect," "project," "intend," "plan," "believe" or other words and terms
of similar meaning. Cephalon's performance and financial results could
differ materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political conditions
affecting the biotechnology and pharmaceutical industries as well as more
specific risks and uncertainties facing Cephalon such as those set forth in
its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect. Therefore, you
should not rely on any such factors or forward-looking statements.
Furthermore, Cephalon does not intend to update publicly any
forward-looking statement, except as required by law. The Private
Securities Litigation Reform Act of 1995 permits this discussion.
SOURCE Cephalon, Inc.
 back to top
Related links:
http://www.cephalon.com
http://www.prnewswire.com/comp/134563.html /
CONTACT:
Media, Sheryl Williams, +1-610-738-6493,
swilliam@cephalon.com, or Investors, Robert (Chip) Merritt,
+1-610-738-6376, cmerritt@cephalon.com, both of Cephalon, Inc.
|
